Sarepta Therapeutics Inc (SRPT) was Reiterated by Wedbush to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 23 from a previous price target of $14 . Wedbush advised their investors in a research report released on Jun 1, 2016.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Sarepta Therapeutics Inc was Downgraded by Leerink Partners to ” Underperform” on May 3, 2016. Sarepta Therapeutics Inc was Downgraded by Jefferies to ” Underperform” on Apr 29, 2016. Shares were Reiterated by RBC Capital Mkts on Apr 26, 2016 to “Sector Perform” and Lowered the Price Target to $ 5 from a previous price target of $7.50 .
On the company’s financial health, Sarepta Therapeutics Inc reported $-1.15 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-1.14.Analysts expectations of $ .18.During the same quarter in the previous year, the company posted $-1.15 EPS.
Sarepta Therapeutics Inc closed down -1.01 points or -4.55% at $21.19 with 65,99,527 shares getting traded on Friday. Post opening the session at $22.25, the shares hit an intraday low of $20.82 and an intraday high of $23.04 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Mar 16, 2016, M Kathleen Behrens (director) purchased 75,000 shares at $15.54 per share price. According to the SEC, on Mar 16, 2016, Ben Gil Price (director) purchased 4,500 shares at $16.70 per share price. On Mar 16, 2016, Richard Barry (director) purchased 75,000 shares at $15.66 per share price, according to the Form-4 filing with the securities and exchange commission.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.